Variation in Visual Outcome to Anti-Vascular Endothelial Growth Factors in Choroidal Neovascular Membrane Developing in Eyes with Previously Untreated Versus Focal Laser-Treated Central Serous Chorioretinopathy

Semin Ophthalmol. 2017;32(6):781-786. doi: 10.1080/08820538.2016.1182556. Epub 2016 Aug 17.

Abstract

Purpose: To report the visual outcome in choroidal neovascular membrane developing (CNVM) in eyes with central serous chorioretinopathy (CSCR) with our without prior focal laser.

Methods: A retrospective case series of eyes with CNVM secondary to CSCR treated with intravitreal anti-VEGF.

Results: Ten eyes of nine patients of CNVM with CSCR who underwent intravitreal anti-VEGF injections were analyzed. Five eyes had CNVM without prior laser photocoagulation, and five eyes developed CNVM after laser photocoagulation for CSCR. Intravitreal injection bevacizumab was given in five eyes and ranibizumab in five eyes. The lasered group had significantly shorter duration of the disease, fewer injections given, and better visual acuity at final follow-up (P <0.05). None had any recurrences of either CSCR or CNVM until the last follow-up.

Conclusion: CNVM in CSCR with prior history of focal laser had better outcome than that developed de novo, without prior history of laser.

Keywords: Anti-vascular endothelial growth factor; central serous chorioretinopathy; choroidal neovascular membrane; focal laser photocoagulation; visual outcome.

MeSH terms

  • Adolescent
  • Adult
  • Angiogenesis Inhibitors / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Central Serous Chorioretinopathy / complications*
  • Central Serous Chorioretinopathy / drug therapy
  • Central Serous Chorioretinopathy / surgery
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / physiopathology
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Laser Coagulation
  • Male
  • Middle Aged
  • Ranibizumab / therapeutic use*
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Visual Acuity / physiology*
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab
  • Ranibizumab